Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Booz Allen Hamilton Holding Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Booz Allen Hamilton Holding Corporation trades at $62.44 (market cap $7.59B). The key difference: Booz Allen Hamilton Holding Corporation is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays a 3.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BAH | |
|---|---|---|
Market Cap | $4.49B | $7.59B |
Sector | Health | Industrials |
52-Week High | $28.06 | $115.95 |
52-Week Low | $20.06 | $59.71 |
Enterprise Value | $3.69B | $10.99B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Booz Allen Hamilton (BAH) trades at $63.31, up 1.38% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $12.0B in 2025 and impressive profitability metrics including 80.17% ROE. Recent developments include strategic AI partnerships with OpenAI and acquisitions to strengthen defense technology capabilities, though the stock faces near-term pressure from civil business weakness.
BAH presents a compelling value opportunity with attractive valuation multiples (P/E 9.03, P/S 0.68) and analyst consensus target of $87.25 representing 38% upside. However, investors face risks from FY27 transition expectations, civil segment pressures, and technical resistance near $64-65 levels. The company's government-focused model provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
